Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Sara Tolaney, MD, MPH, Dana Farber Cancer Institute, Boston, MA, discusses tumor mutational burden and PTEN alterations as molecular correlates of response to PD-1/L1 blockade in metastatic triple-negative breast cancer (mTNBC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).